Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 121

Results For "CEO"

1937 News Found

JB Pharma acquires 4 paediatric brands from Dr Reddy’s Laboratories
News | July 01, 2022

JB Pharma acquires 4 paediatric brands from Dr Reddy’s Laboratories

The total covered market size of four brands – Z&D, Pediclory, Pecef & Ezinapi combined is Rs 1800 crores


NADMED brings first CE-marked NAD+ analysis kit to the market
Medical Device | June 30, 2022

NADMED brings first CE-marked NAD+ analysis kit to the market

NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites


Experts call for “Disability Inclusive Health Care System” to address health inequity
Healthcare | June 30, 2022

Experts call for “Disability Inclusive Health Care System” to address health inequity

We must try to make the health care system more accessible for people with disabilities


Apollo Education UK launches the Apollo International Clinical Fellowship Programme
News | June 29, 2022

Apollo Education UK launches the Apollo International Clinical Fellowship Programme

Doctors will study for a Master of Surgery or Master of Medicine degree at Edge Hill University.


Wacker to build biotechnology center in Munich
Biotech | June 28, 2022

Wacker to build biotechnology center in Munich

The research here will mainly concentrate on the manufacturing process of biopharmaceuticals, especially in the area of advanced medicines, as well as the fermentation-based manufacture of ingredients for foods and food supplements


Cipla to further invest Rs 25.90 crore to acquire 22.02% stake in GoApptiv
Digitisation | June 28, 2022

Cipla to further invest Rs 25.90 crore to acquire 22.02% stake in GoApptiv

Strengthens investment in channels of the future to expand patient reach


Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against omicron
News | June 27, 2022

Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against omicron

Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine


Novartis commits US$ 250 million to the fight against NTDs and malaria
Public Health | June 24, 2022

Novartis commits US$ 250 million to the fight against NTDs and malaria

This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.


Silo Pharma expands license agreement and patent portfolio
News | June 24, 2022

Silo Pharma expands license agreement and patent portfolio

Silo enters into commercial evaluation license agreement for next generation liposomes


Biolexis and Akston Biosciences announce encouraging results of thermostable 2nd Gen COVID-19 vaccine
News | June 24, 2022

Biolexis and Akston Biosciences announce encouraging results of thermostable 2nd Gen COVID-19 vaccine

An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.